BRPI0820474A2 - método de tratamento de uma doença, uso de composto, e, composto - Google Patents

método de tratamento de uma doença, uso de composto, e, composto

Info

Publication number
BRPI0820474A2
BRPI0820474A2 BRPI0820474A BRPI0820474A BRPI0820474A2 BR PI0820474 A2 BRPI0820474 A2 BR PI0820474A2 BR PI0820474 A BRPI0820474 A BR PI0820474A BR PI0820474 A BRPI0820474 A BR PI0820474A BR PI0820474 A2 BRPI0820474 A2 BR PI0820474A2
Authority
BR
Brazil
Prior art keywords
compound
disease
treating
Prior art date
Application number
BRPI0820474A
Other languages
English (en)
Inventor
Batra Aneil
Chon Jin
Dragheim Marianne
Moore Nicholas
Original Assignee
H Lundebeck As
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundebeck As, Takeda Pharmaceuticals North America Inc filed Critical H Lundebeck As
Publication of BRPI0820474A2 publication Critical patent/BRPI0820474A2/pt
Publication of BRPI0820474B1 publication Critical patent/BRPI0820474B1/pt
Publication of BRPI0820474B8 publication Critical patent/BRPI0820474B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0820474A 2007-11-13 2008-11-12 uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo BRPI0820474B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (3)

Publication Number Publication Date
BRPI0820474A2 true BRPI0820474A2 (pt) 2017-05-23
BRPI0820474B1 BRPI0820474B1 (pt) 2020-08-04
BRPI0820474B8 BRPI0820474B8 (pt) 2021-05-25

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820474A BRPI0820474B8 (pt) 2007-11-13 2008-11-12 uso do composto 1-[2-(2,4-dimetil-fenil-sulfanil)-fenil]-piperazina ou de sais farmaceuticamente aceitáveis do mesmo

Country Status (30)

Country Link
US (5) US9278096B2 (pt)
EP (3) EP3115050A1 (pt)
JP (2) JP5603244B2 (pt)
KR (1) KR101536023B1 (pt)
CN (1) CN102014908A (pt)
AR (1) AR069260A1 (pt)
AT (1) ATE537829T1 (pt)
AU (1) AU2008323390B2 (pt)
BR (1) BRPI0820474B8 (pt)
CA (1) CA2705163C (pt)
CL (1) CL2008003363A1 (pt)
CO (1) CO6270322A2 (pt)
CY (2) CY1112646T1 (pt)
DK (2) DK2219647T4 (pt)
EA (1) EA027783B1 (pt)
ES (2) ES2591110T3 (pt)
HR (2) HRP20120144T4 (pt)
HU (1) HUE029588T2 (pt)
IL (1) IL205466A (pt)
LT (1) LT2431039T (pt)
MX (1) MX2010004688A (pt)
NZ (1) NZ585247A (pt)
PL (2) PL2219647T3 (pt)
PT (2) PT2219647E (pt)
RS (2) RS52256B2 (pt)
SG (1) SG10201405001XA (pt)
SI (2) SI2431039T1 (pt)
TW (1) TW200932233A (pt)
WO (1) WO2009062517A1 (pt)
ZA (1) ZA201003350B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
GEP20135950B (en) 2009-08-24 2013-10-25 H Lundbeck As New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
SI2667715T1 (sl) * 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
MX368870B (es) * 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3799873A1 (en) * 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
BR112018003930A2 (pt) 2016-07-01 2018-09-25 H Lundbeck As regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) * 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
CA2521258C (en) 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
KR101627901B1 (ko) * 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
GEP20135950B (en) 2009-08-24 2013-10-25 H Lundbeck As New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine

Also Published As

Publication number Publication date
HUE029588T2 (en) 2017-03-28
US11628166B2 (en) 2023-04-18
CY1117978T1 (el) 2017-05-17
SI2431039T1 (sl) 2017-01-31
PL2431039T3 (pl) 2016-12-30
RS52256B (sr) 2012-10-31
RS52256B2 (sr) 2020-11-30
ES2379419T3 (es) 2012-04-25
ATE537829T1 (de) 2012-01-15
RS55147B1 (sr) 2016-12-30
BRPI0820474B8 (pt) 2021-05-25
HRP20161121T1 (hr) 2017-01-27
US20210093631A1 (en) 2021-04-01
SI2219647T1 (sl) 2012-06-29
TW200932233A (en) 2009-08-01
AR069260A1 (es) 2010-01-06
US20110201617A1 (en) 2011-08-18
EP2431039B1 (en) 2016-07-20
EA201070598A1 (ru) 2010-10-29
IL205466A0 (en) 2010-12-30
SG10201405001XA (en) 2014-10-30
HRP20120144T4 (hr) 2020-11-13
JP5603244B2 (ja) 2014-10-08
US9744166B2 (en) 2017-08-29
EA027783B1 (ru) 2017-09-29
MX2010004688A (es) 2010-09-09
JP2014193891A (ja) 2014-10-09
AU2008323390A1 (en) 2009-05-22
EP2219647A1 (en) 2010-08-25
ZA201003350B (en) 2011-08-31
US9278096B2 (en) 2016-03-08
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
WO2009062517A1 (en) 2009-05-22
DK2219647T4 (da) 2020-09-28
CA2705163A1 (en) 2009-05-22
CN102014908A (zh) 2011-04-13
EP2219647B2 (en) 2020-07-29
BRPI0820474B1 (pt) 2020-08-04
JP5841636B2 (ja) 2016-01-13
CA2705163C (en) 2013-02-12
ES2591110T3 (es) 2016-11-24
NZ585247A (en) 2012-03-30
CY1112646T1 (el) 2016-02-10
IL205466A (en) 2014-06-30
KR20100099115A (ko) 2010-09-10
PT2431039T (pt) 2016-09-29
LT2431039T (lt) 2016-10-10
AU2008323390B2 (en) 2013-10-24
EP2219647B1 (en) 2011-12-21
KR101536023B9 (ko) 2023-03-29
EP2431039A1 (en) 2012-03-21
CO6270322A2 (es) 2011-04-20
JP2011503125A (ja) 2011-01-27
US20240082239A1 (en) 2024-03-14
DK2219647T3 (da) 2012-03-19
DK2431039T3 (en) 2016-09-26
KR101536023B1 (ko) 2015-07-10
US20160228430A1 (en) 2016-08-11
ES2379419T5 (es) 2021-05-04
SI2219647T2 (sl) 2020-11-30
HRP20120144T1 (en) 2012-04-30
EP3115050A1 (en) 2017-01-11
PT2219647E (pt) 2012-03-16
CL2008003363A1 (es) 2009-06-05

Similar Documents

Publication Publication Date Title
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
FI20075978A0 (fi) Järjestely ja menetelmä
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PL2190883T3 (pl) Sposób obróbki biomasy
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0812176A2 (pt) Método de cimentar poço
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
EP2091257A4 (en) encoder
BRPI0813770A2 (pt) Composição, e, uso de uma composição
EP2145244A4 (en) MOUSE
BRPI0809573A2 (pt) composição, e, método
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0813670A2 (pt) Compostos para tratamento
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0820644A2 (pt) método de preparação de uma composição, e, composição
BRPI0814167A2 (pt) Composição, e, método
DK2173831T3 (da) Brøndbehandling
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
FR2908035B1 (fr) Implant interepineux
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: H. LUNDEBECK A/S (US) ; TAKEDA PHARMACEUTICALS U.S

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: LIBBS FARMACEUTICA LTDA - 870210011554 - 03/02/2021

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.000768/2022-78 ORIGEM: JUIZO SUBSTITUTO DA 13A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5083535-29.2021.4.02.5101 NULIDADE DE PATENTE DE INVENCAO AUTOR: ALTHAIA S.A INDUSTRIA FARMACEUTICA REU(S): H. LUNDBECK A/S, TAKEDA PHARMACEUTICALS U.S.A., INC. E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.007244/2021-27 ORIGEM: 21A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1049910-61.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: H. LUNDBECK A/S E TAKEDA PHARMACEUTICALS U.S.A., INC. REU(S): LIBBS FARMACEUTICA LTDA E INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL